Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Conditions
Interventions
Lenabasum 20 mg
Lenabasum 5 mg
+1 more
Locations
54
United States
HonorHealth Neurology
Phoenix, Arizona, United States
Mayo Clinic
Scottsdale, Arizona, United States
Attune Health Center
Beverly Hills, California, United States
UCLA Division of Rheumatology
Los Angeles, California, United States
Denver Arthritis Clinic
Denver, Colorado, United States
Georgetown University
Washington D.C., District of Columbia, United States
Start Date
December 17, 2018
Primary Completion Date
March 31, 2021
Completion Date
October 5, 2021
Last Updated
August 16, 2022
NCT04402086
NCT07160205
NCT07374107
NCT07089121
NCT06371417
NCT02945345
Lead Sponsor
Corbus Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions